Aastrom Biosciences, Inc. Enters Into $15 Million Equity Commitment With Lincoln Park Capital
Published: Jan 27, 2014
ANN ARBOR, Mich., Jan. 27, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, announced today that it has entered into a stock purchase agreement with Lincoln Park Capital Fund, LLC ("Lincoln Park"), an institutional investor. Under the terms of the agreement, Aastrom has the right to sell up to $15 million in shares of common stock to Lincoln Park over a thirty-month period subject to certain limitations and conditions set forth in the purchase agreement.
Help employers find you! Check out all the jobs and post your resume.